Table 3.

Total number and per cent (n/%) of participants reporting swelling, erythema or induration after Tdap injection

	Swelling (N=793)	Erythema (N=793)	Induration* (N=326)
None	733 (92.4)	747 (94.2)	287 (88.0)
Circumference of event (cm)	(n=60)	(n=46)	(n=39)
>0.0 to <1.0	33 (4.2)	25 (3.2)	21 (6.4)
>1.0 to <2.5	12 (1.5)	10 (1.3)	12 (3.7)
>2.5 to <5.0	12 (1.5)	8 (1.0)	6 (1.8)
>5.0 to <10.0	2 (0.3)	3 (0.4)	−
>10.0 to <15.0	1 (0.1)	−	−
Onset of event after injection (h)	(n=60)	(n=46)	(n=39)
0–24	44 (73.3)	27 (58.7)	15 (38.5)
25–48	16 (26.7)	16 (34.8)	22 (56.4)
>49	–	3 (6.5)	2 (5.1)
Resolution of event (h)	(n=60)	(n=46)	(n=39)
0–24	14 (23.3)	13 (28.3)	6 (15.4)
25–48	15 (25.0)	10 (21.7)	11 (28.2)
>49	31 (51.7)	23 (50.0)	22 (56.4)

*Northern study data only.